OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas Article

Bell, EH, Zhang, P, Aldape, K et al. (2017). OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas . NEURO-ONCOLOGY, 19(suppl_3), iii2-iii3. 10.1093/neuonc/nox036.006

cited authors

  • Bell, EH; Zhang, P; Aldape, K; McElroy, J; Mehta, M; Fleming, J; Liu, Z; Coons, S; Johnson, D; Chakravarti, A

authors

publication date

  • May 1, 2017

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 4 Detection, screening and diagnosis
  • 4.2 Evaluation of markers and technologies
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Genetics
  • Neurosciences
  • Prevention
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • iii2

end page

  • iii3

volume

  • 19

issue

  • suppl_3